Sermorelin Research Overview: GHRH Analogue for GH Secretion Studies

Overview

Sermorelin (GHRH 1-29 NH2) is a synthetic analogue of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It was the first GHRH analogue approved by the FDA for diagnostic and therapeutic use in growth hormone deficiency, making it one of the most clinically validated peptides in the GH secretagogue class.

---

Mechanism of Action

Sermorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. This binding triggers a cascade:

1. Receptor activation and adenylyl cyclase stimulation
2. Increased intracellular cAMP
3. Protein kinase A activation
4. GH gene transcription and synthesis
5. Pulsatile GH secretion into circulation

Unlike exogenous recombinant human GH (rhGH), sermorelin stimulates the pituitary to produce and release GH endogenously, preserving the natural pulsatile release pattern.

---

Pharmacokinetics

| Parameter | Value | |-----------|-------| | Half-life | 10-20 minutes | | Route | Subcutaneous or IV | | Peak GH response | 30-60 minutes post-administration | | Duration of GH elevation | 2-4 hours | | Metabolism | Proteolytic cleavage |

---

Clinical Research History

Diagnostic Applications: Sermorelin stimulation tests were used clinically to assess pituitary GH reserve. A blunted GH response to sermorelin indicated pituitary dysfunction or GH deficiency.

Pediatric GH Deficiency: Clinical trials demonstrated that sermorelin was effective at stimulating GH secretion and promoting linear growth in children with GH deficiency, leading to FDA approval in 1997.

Adult Somatopause Research: Studies in older adults investigated whether sermorelin could reverse age-related GH decline. Research showed that sermorelin administration increased GH and IGF-1 levels in older subjects, with improvements in sleep quality and body composition markers.

---

Sermorelin vs. CJC-1295

| Parameter | Sermorelin | CJC-1295 (non-DAC) | CJC-1295 DAC | |-----------|-----------|---------------------|---------------| | Half-life | 10-20 min | ~30 min | 6-8 days | | GH pulse pattern | Physiological | Near-physiological | Sustained | | IGF-1 elevation | Moderate | Moderate | Significant | | Clinical data | Extensive | Limited | Moderate |

Sermorelin's primary advantage over CJC-1295 is its extensive clinical validation and well-characterized safety profile.

---

Summary

Sermorelin remains one of the most clinically validated GHRH analogues available for research. Its physiological mechanism of action, extensive safety data, and well-characterized pharmacokinetics make it a valuable reference compound for GH secretagogue research.

See Also: Growth Hormone Peptides: GHRPs, GHRHs and Secretagogues | Ipamorelin + CJC-1295 Combination Research

Shop Research Grade: View Sermorelin Research Grade →